Zynex (ZYXI) News & Sentiment

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ZYNEX, INC. (ZYXI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On March 11, 2025, after market hours, Zynex released its fourth quarter and full y.

ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) complied with federal securities laws. On March 11, 2025, Zynex reported its financial and operation results for the fourth quarter and full year ended December 31, 2024, announcing that “fourth quarter revenue was less than expected. The shortfall was due to slower than normal payments from certain payers and we were recently notified that Tricare has temporarily suspended payments as they review prior claims.” Following this announcement, the price of the Company's stock dropped.

Zynex, Inc. specializes in non-invasive pain management and patient monitoring, with promising advancements like the NiCO pulse oximeter targeting accurate readings for diverse skin tones. Despite disappointing Q4 2024 results and reimbursement challenges, Zynex aims for long-term growth with cost-cutting measures and a strategic market entry plan for NiCO. Valuation concerns arise from high current P/E ratios, but projected forward P/E compression suggests potential deep-value in the growing medical device market.

Zynex Inc (NASDAQ:ZYXI) has reported its financial results for the fourth quarter and the full year 2024, with full-year revenue growing 4% to reach $192.4 million. The medical technology company specializing in non-invasive devices for pain management, rehabilitation and patient monitoring saw 16% year-over-year growth in orders in 2024.

ENGLEWOOD, Colo. , March 3, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, March 11, 2025 at 4:15 PM Eastern Time to discuss its financial results for the fourth quarter and year ended December 31, 2024.

Zynex Inc (NASDAQ:ZYXI) COO Anna Lucsok shared insights earlier this week about the company's operational strategies and future growth plans in an interview with Proactive. Lucsok discussed the company's strong performance in sales and reimbursement, as well as its mission to provide non-opioid pain management solutions.

Zynex Inc (NASDAQ:ZYXI) continues to expand its portfolio of innovative, non-invasive medical devices targeting pain management, rehabilitation, and pain monitoring.   The company's flagship NexWave product is a multi-modality electrotherapy device that combines various therapeutic modalities to provide effective pain relief.

VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually ENGLEWOOD, Colo. , Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States.

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to employee dedication and innovative pain management products like braces and cold therapy devices.